⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Ignis Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Ignis Therapeutics
↗Shanghai, China
Ignis Therapeutics is a Shanghai-based biotechnology company founded in 2020, dedicated to developing and commercializing innovative therapies for central nervous system (CNS) disorders. The company focuses on addressing unmet medical needs through a pipeline that includes both in-licensed assets and in-house R&D, covering conditions such as epilepsy, Parkinson's disease, narcolepsy, and schizophrenia.
Ignis operates across the entire value chain, including R&D, clinical development, regulatory affairs, manufacturing, and commercialization. Supported by significant venture capital, including a $185 million Series A financing, the company maintains a strategic partnership with SK Biopharmaceuticals to bring advanced CNS treatments to the Greater China market.
CLASSIFICATION
SIZE & FINANCIALS
Employees:100+
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$185M
Investors:6 Dimensions Capital, SK Biopharmaceuticals, Ruentex Group, KB Investment, Mubadala Investment Company, HBM Healthcare Investments, Goldman Sachs
PIPELINE
Stage:Phase 3
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:0
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:SK Biopharmaceuticals (Licensing and collaboration for CNS assets), STADA Arzneimittel AG (Licensing for apomorphine subcutaneous injection)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Eileen Long - CEO & Chief Medical Officer
Qiang Li - Chief Operating Officer
Board Members:Leon Chen
LINKS
Website:ignistherapeutics.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ignis Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.